{"id":"NCT00430248","sponsor":"Takeda","briefTitle":"Efficacy and Safety of Oral Febuxostat in Participants With Gout","officialTitle":"A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-02","primaryCompletion":"2008-03","completion":"2008-03","firstPosted":"2007-02-01","resultsPosted":"2009-07-16","lastUpdate":"2012-02-02"},"enrollment":2269,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Gout"],"interventions":[{"type":"DRUG","name":"Febuxostat","otherNames":["TMX-67","Tei-6720","Uloric"]},{"type":"DRUG","name":"Febuxostat","otherNames":["TMX-67","Tei-6720","Uloric"]},{"type":"DRUG","name":"Allopurinol","otherNames":["Zyloprim"]}],"arms":[{"label":"Febuxostat 40 mg QD","type":"EXPERIMENTAL"},{"label":"Febuxostat 80 mg QD","type":"EXPERIMENTAL"},{"label":"Allopurinol 200 mg or 300 mg QD","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy and safety of febuxostat, once Daily (QD), to allopurinol in subjects with hyperuricemia and gout.","primaryOutcome":{"measure":"Percentage of Subjects Whose Serum Urate Level is <6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit.","timeFrame":"Last Visit on treatment (up to 6 months)","effectByArm":[{"arm":"Febuxostat 40 mg QD","deltaMin":45.2,"sd":null},{"arm":"Febuxostat 80 mg QD","deltaMin":67.1,"sd":null},{"arm":"Allopurinol 200 mg or 300 mg QD","deltaMin":42.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG002","p":"0.233"},{"comp":"OG001 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":9},"locations":{"siteCount":258,"countries":["United States"]},"refs":{"pmids":["20370912","21353107","22132950","22052584","23683134","22436129","22316106"],"seeAlso":["http://general.takedapharm.com/content/file.aspx?applicationcode=6C7C39D8-5D09-453B-BF30-696A4AB88E62&fileTypeCode=ULORICPI"]},"adverseEventsSummary":{"seriousAny":{"events":19},"commonTop":["Upper Respiratory Tract Infections","Liver Function Analyses","Diarrhoea (Excluding Infective)","Musculoskeletal and Connective Tissues Signs and Symptoms NEC"]}}